PubMed Health⌕ Search

Biomedical subjects

D T Abdurakhmanov

Publications and source records attributed to D T Abdurakhmanov.

8 recordsLinked to original sources
PubMed2004

[Vascular purpura associated with chronic diffusive hepatic pathologies].

The study results related with the rate of vascular purpura in 660 patients with different-type chronic diffusive hepatic pathologies both of the viral and other natures are described in the paper. The main regularities characterizing the phenomenon (spread and possible cause of purpura development) are defined. According to an analysis of actual materials, dermal vasculitis is not an exclusive feature of virus-associated hepatitis or liver cirrhosis. Vascular purpura can be regarded, on the basis of the obtained data, as a universal sign typical of any liver pathologies.

Adolescent↗
PubMed2003

[Clinico-morphological characteristics of chronic HbcAg-negative HBV infection with a normal level of aminotransferases].

To study clinicomorphological characteristics and a course of chronic HbeAg-negative HBV-infection with a normal level of aminotransferases, 38 patients whose blood contained HbsAg, HBVDNA and anti-Hbe were divided into 2 groups: with normal (20 patients, test group) and elevated (18 patients, control group) level is of aminotransferases. All the patients' livers were studied morphologically and semiquantitative test for viremia was made. Compared to the controls, the test group patients had low morphological activity (3.4 +/- 1.1 and 8.7 +/- 3.2, respectively, p < 0.005), a fibrosis degree (1.1 +/- 0.4 and 2.3 +/- 1.4 score, respectively p < 0.01) and viremia (log 10 - 3.7 +/- 1.2 vs 6.1 +/- 2.4, p < 0.05). The monofactor analysis has established that viremia 10(5) cop/ml maximum significantly associates with a normal level of aminotransferases (chi-square = 7.89, p = 0.005) while viremia higher than 10(7) cop/ml strongly correlates with a high level of aminotransferases (chi-square = 4.11, p = 0.043). Follow-up of patients with a normal level of aminotransferases for 28 +/- 24 months (6-72 months) showed neither deterioration of the clinical status nor laboratory changes. Thus, patients having anti-HBe and no HbeAg with a normal level of ALT and low viremia (under 10(5) cop/ml) can be considered inactive carriers of HbsAg. In spite of a relatively favourable prognosis, these patients should be followed up for a long time.

Adult↗
PubMed2003

[Efficacy of lamivudine in HBeAg-negative chronic hepatitis B].

The necessity of the search for new drugs to treat chronic hepatitis B (CHB) is explained by the necessity to prevent hepatic cirrhosis (HC) and hepatocellular carcinoma. Treatment of HBeAg-negative CHB rests on the same principles as of HBeAg-positive one. Efficacy of nucleoside analogue lamivudin is well studied in HBeAg-positive CHB. The aim of this study was to evaluate lamivudine efficacy in therapy of HBeAg-negative CHB. Lamivudine (epivir--150 mg/day or zeffix--100 mg/day) was given for 1 year to 10 patients (5 males, 5 females, mean age 49.5 +/- 13.5). Their blood serum contained no HBeAg but contained HBeAb and HBVDNA. Chronic hepatitis was verified morphologically in 9 patients of whom 2 had HC and 2 developing HC. Moderate activity of the disease was in 4 patients, low--in 5. All the patients had a high ALT level (150 +/- 140 U/l, 60-528 U/l, high normal value 40 U/l). ALT and HBV DNA in the serum were examined by polymerase chain reaction in the course of treatment and for 6 months after its end. To the end of the treatment a complete response (absence of HBVDNA and normalization of ALT) was achieved in 8 (80%) patients. 5 (63%) of them 2-4 months after the end of the treatment had the exacerbation with appearance of HBVDNA in the serum and elevation of ALT level. A persistent response (6 months after lamivudin treatment) was in 3 (30%) patients, in 2 of them HBsAg was not detected. Lamivudin therapy is effective in HBeAg-negative CHB. In this study a high baseline level of ALT was the factor predisposing to a lasting response to treatment.

Adolescent↗
PubMed2002

[Chronic HBV infection].

Chronic hepatitis B remains one of the most wide-spread and serious viral infections in humans worldwide and may lead to cirrhosis and cancer of the liver. Eradication of the virus depends primarily on T-cell immune reaction aimed at lysis of the infected hepatosytes and suppression of the virus replication without cell death due to secretion of proinflammatory cytokines. Pathogenesis of the disease is markedly influenced by viral mutations. Persistent hepatitis B virus infection can be controlled in 25-40% patients by alpha-interferon and nucleoside lamivudine therapy.

Hepatitis B, Chronic↗
PubMed2001

[Isosorbide-5-mononitrate (mono mac) in the prevention of bleeding from esophageal varicose veins in patients with liver cirrhosis].

Varicose esophageal veins bleeding is one of severe complications of hepatic cirrhosis. This complication is effectively managed with combination of beta-blockers with nitrates. Of the latter, optimal is isosorbite-5-mononitrate (mono mac). Its minimal risk of development of nitrate tolerance and pharmacokinetics does not depend on hepatic or renal function. A single dose of mono mac varies from 10 to 50 mg. The individual dose is selected by a fall in systolic blood pressure at rest (by 15-20 mm Hg) above 100 mm Hg. In appearance of serious headache nitrates are followed by beta-blockers monotherapy. It is inferred that isosorbite-5-mononitrate (mono mac) is effective in prophylaxis of hemorrhage from varicose veins of the esophagus both in beta-blockers and as monotherapy when beta-blockers are contraindicated.

Adrenergic beta-Antagonists↗